Xanax XR Extended-Release Tablets Recalled for Failed Dissolution Specifications
Viatris Inc recalls Xanax XR (alprazolam) 3 mg extended-release tablets due to failed dissolution specifications. Affected tablets may not break down properly, potentially reducing medication effectiveness.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall involving a quality control failure that affects drug efficacy. The source reports no illnesses or injuries, and the hazard—failed dissolution specifications—represents a risk-of-harm product where injury has not yet been reported.
Plain-English summary
Viatris Inc is recalling Xanax XR (alprazolam) extended-release tablets, 3 mg, in 60-count bottles. The recall affects 110 bottles distributed nationwide in the United States under NDC 0009-0068-07, lot DX7983 with an expiration date of 02/28/2023. The tablets failed to meet dissolution specifications required by quality control standards.
Dissolution specifications ensure that extended-release tablets break down properly in the digestive tract to release medication gradually as designed. Tablets that fail these standards may not work as intended, potentially affecting treatment effectiveness and drug absorption.
Consumers who have purchased Xanax XR tablets from lot DX7983 should contact their pharmacist or healthcare provider immediately. They should not use the recalled product and should follow their healthcare provider's guidance regarding continued treatment.
The recalled product
- Product
- Xanax XR (alprazolam) extended-release tablets, 3 mg, 60-count bottle, Rx only, Distributed by Pharmacia & Upjohn Co, Division of Fizer Inc, NY, NY 10017, NDC 0009-0068-07.
- Manufacturer
- Viatris Inc
- Category
- Drug
- Affected units
- 110
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: DX7983
- exp. date 02/28/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Viatris Inc
See all →- HighXanax XR 3 mg extended-release tablets fail dissolution specifications
FDA (Drugs) · 2026-04-15
- ModeratePrescription Drug Cardura XL Recalled for Out-of-Specification Impurity
FDA (Drugs) · 2025-01-22
- HighPrescription Drug Cardura Recalled for Specification Failures in Manufacturing
FDA (Drugs) · 2025-01-22
- HighLevothyroxine Sodium Tablets recalled nationwide for potency failures
FDA (Drugs) · 2024-12-18
- HighLevothyroxine Sodium Tablets Recalled Due to Potency Failures
FDA (Drugs) · 2024-12-18
Same hazard · failed dissolution
See all →- ModerateNovartis Recalls Diovan Valsartan Tablets Due to Failed Dissolution Specifications
FDA (Drugs) · 2026-08-19
- LowSupernus Recalls Trokendi XR Capsules for Failed Dissolution Specifications
FDA (Drugs) · 2026-07-29
- HighAscend amlodipine and olmesartan tablets failed dissolution specifications
FDA (Drugs) · 2026-06-10
- HighLannett niacin extended-release tablets failed dissolution specifications during stability
FDA (Drugs) · 2026-06-10
- HighMajor Pharmaceuticals memantine extended-release capsules fail dissolution specifications
FDA (Drugs) · 2026-04-22